Educational information, reviewed by Ryan Arvizo, FNP-C. Current as of September 2026. Not medical advice. Prices below were read from the manufacturers’ own pages on 2026-09-26 and can change.
If you opened a letter from your plan, or a pharmacy told you the claim was rejected, you are not alone. In 2025, fewer than half of the largest employers covered GLP-1 medications for weight loss, and smaller employers covered them far less often. Several state Medicaid programs, including Arizona’s, do not cover GLP-1s for weight loss at all, and a number of state-employee plans have narrowed or ended coverage. Coverage for type 2 diabetes is a separate question and usually continues.
Here is the map of what you can lawfully do next, in plain language.
Option 1: brand-name medication, self-pay
Both manufacturers now sell directly to patients at set cash prices, no insurance involved.
- Wegovy (semaglutide): the pill starts at $149 per month at the lowest dose; the injectable pen is $199 per month for the first two fills for new self-pay patients through December 31, 2026, then $349 per month.
- Zepbound (tirzepatide): vials start at $299 per month at the starting dose, $399 at the next dose, and $449 per month at maintenance doses when refilled within 45 days; the price is higher if a refill lapses.
These are FDA-approved products with the strongest evidence and the clearest status. A prescription is still required, and a provider still needs to decide whether the medication is appropriate for you.
Option 2: a provider-led program that may prescribe compounded medication
Compounded GLP-1 medication is prepared for an individual patient by a state-licensed pharmacy on a prescription. It is not FDA-approved, and after the FDA shortage ended the lawful path narrowed to patient-specific compounding in specific clinical circumstances. It remains a provider decision, not a menu choice. Our plain-language guide on whether compounded semaglutide is still legal in 2026 explains where the rules stand.
At BioPeakRx, care starts with a free Provider Evaluation — the $110 fee was removed, so losing your coverage does not also cost you to find out your options. If a licensed provider determines therapy is appropriate, your medication is one all-in monthly price that already includes provider care, monitoring and shipping, with no membership fee, and any medication is billed separately at a price you see before you pay. Our current medication prices are on the pricing page.
Option 3: if you are 65 or older
A Medicare pilot that began July 1, 2026 lets some Part D members get brand-name Wegovy, Zepbound, or Foundayo for a $50 monthly copay if they meet the medical criteria. If you are on Medicare, check that program before paying cash.
What to avoid
- “Research use only” vials and unverified online sellers. They are not made or tested for people, and no one checks your labs.
- Anyone who promises the same drug for a fraction of the price with no evaluation. The FDA sent warning letters to 30 telehealth companies in early 2026 over misleading claims about compounded GLP-1s.
- Stopping or changing your medication on your own. Talk to a provider first about how to transition.
How to start
A Provider Evaluation is the honest place to sort this out. Bring your current medication name and dose, when you last took it, and any recent labs. Your provider will tell you which option fits, including whether a brand-name self-pay program is the right answer for you.
Sources
- KFF, 2025 Employer Health Benefits Survey (GLP-1 weight-loss coverage by firm size)
- KFF, Medicaid Coverage of and Spending on GLP-1s (January 2026)
- KFF, What to Know About the BALANCE Model and the Medicare GLP-1 Bridge
- NovoCare, Wegovy self-pay pricing
- LillyDirect, Zepbound self-pay pricing
- FDA, FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s
This information is educational and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved. Treatments require evaluation by a licensed provider.